生技藥品開發和受託製造廠商市場按服務類型、表現系統、治療類別、開發階段和最終用戶分類 - 全球預測 2025-2032

預計到 2032 年，生技藥品受託製造廠商市場將成長至 191.8 億美元，複合年成長率為 7.69%。

本文以精闢的視角，重點闡述了生技藥品CDMO在技術、監管和商業性優勢方面的夥伴關係和營運重點是如何演變的。

生技藥品受託製造領域正經歷一場策略重組，其驅動力來自技術進步、日益嚴格的監管要求以及愈演愈烈的競爭格局。各種規模的企業都在重新評估如何與外部製造商合作，將複雜的分子從發現階段推進商業化階段，同時也要應對供應鏈脆弱性和勞動力短缺等問題。先進的表達系統、不斷發展的治療模式以及研發人員的營運需求之間的相互作用，正在為品質、速度和靈活性設定新的標準，現有企業必須滿足這些標準才能保持競爭力。

在此背景下，產業相關人員日益重視能夠提供技術深度和商業性靈活性的端到端夥伴關係關係。包括原料藥和製劑整合能力在內的創新服務模式正在重新定義客戶期望，並推動研發階段的快速前進。此外，對一次性技術、模組化設施和數位化流程控制的投資並非僅僅是成本控制策略，而是支持擴充性和合規性的策略推動因素。總而言之，這些因素正在顯著改變申辦方選擇合作夥伴、建立合約和製定長期供應策略的方式，從而創造一個更具韌性、創新主導的市場環境。

快速的技術進步、策略整合以及贊助商期望的改變，正在生技藥品生產領域創造新的競爭動態和夥伴關係模式。

隨著申辦者和服務供應商適應新的需求，生技藥品生產生態系統正經歷變革性的變化：更快的臨床試驗時間、更嚴格的監管審查以及需要靈活的生產能力來適應不同的給藥方式。表現系統和下游製程的進步提高了產量和產品一致性，而分析和數位化製程監控技術的同步發展則提高了人們對可追溯性和品質保證的期望。這種技術變革與策略轉變相輔相成：越來越多的申辦者正從交易型外包轉向策略合作，後者包括共同開發和風險共擔機制。

同時，市場動態正在推動整合和專業化。大量策略性投資正湧向支持複雜單株抗體和細胞療法供應鏈中哺乳動物細胞表達能力的建設，而一些專注於特定領域的供應商則憑藉最佳化的微生物系統，在快速重組蛋白生產方面脫穎而出。這種脫節促使申辦方採用混合籌資策略，將靈活的小規模早期研發能力與強大的商業化規模合作夥伴結合，以支援後期生產。因此，長期供應商關係、平台技術投資以及區分表現系統和研發階段的能力正成為競爭優勢的核心決定因素。政策制定者和監管機構也在透過強調供應鏈透明度和品質指標來影響這一轉變。

了解預期貿易政策變化和關稅調整將如何改變生技藥品研發和生產中的採購、產能分配和供應商策略

預計2025年關稅波動和貿易政策調整將為生技藥品供應鏈、籌資策略和跨境生產夥伴關係帶來複雜的挑戰。關稅可能對關鍵原料、一次性耗材以及灌裝包裝環節的某些組件的到岸成本產生重大影響，迫使企業重新評估採購區域和合約條款。為此，申辦方和契約製造可能會加快供應商多元化，建立區域採購中心，或重新談判長期供應協議，以降低潛在的成本波動並維持生產計劃。

除了直接投入成本外，關稅主導的變化也會對計劃規劃和產能分配產生間接影響。例如，某些設備和耗材進口關稅的提高可能會促使企業將部分生產流程（尤其是那些涉及特殊法律規範或依賴低溫運輸的流程）遷回國內。此類措施可能會改變資本部署決策，使企業優先投資於模組化、可移動的資產，進而降低跨國關稅風險。此外，隨著企業尋求透過多段運輸路線和本地化倉儲來規避關稅風險，物流可能會變得更加複雜。重要的是，監管合規仍然是不可妥協的。採購和製造地的調整必須考慮到檢驗要求和供應鏈透明度義務，以避免下游批准受阻。總而言之，週詳的方案規劃、靈活的合約條款以及加強與供應商的關係，將是減輕貿易政策變化對生技藥品研發和商業化累積影響的關鍵工具。

細分市場分析表明，服務類型、表達平台、治療領域、研發階段需求和最終用戶畫像是驅動CDMO能力和策略重點的關鍵因素。

透過細緻的市場細分，我們發現不同服務類型、表達系統、治療類別、研發階段和最終用戶的需求促進因素、營運要求和價值提案有顯著差異。根據服務類型，市場可分為產品服務和原料藥服務，二者均需要獨特的技術能力和監管流程，並導致不同的合作夥伴選擇標準。在哺乳動物系統中，複雜的糖基化蛋白需要深厚的專業知識，例如細胞株、 細胞株和Ns0細胞株；而微生物方法，例如大腸桿菌和酵母，則擅長快速、經濟高效地生產結構相對簡單的分子。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 擴大細胞和基因療法生產能力，以滿足日益成長的個人化醫療需求
• 增加一次性生物反應器的使用，以提高操作靈活性並降低污染風險。
• 實施連續的上下游生物程序，以縮短產品上市時間
• 將數位雙胞胎技術整合到生物製藥領域，用於即時監測和製程最佳化
• CDMO與製藥創新者建立策略夥伴關係，以擴大抗體藥物複合體
• 在生物製造中實施用於線上品管的先進製程分析技術平台
• 開發模組化設施設計，以實現多產品生物製藥管線產能的快速擴張。
• 利用人工智慧驅動的預測性維護，最大限度地減少生物製藥生產設施的非計劃性停機時間
• 投資永續生產方法，以減少生物製藥行業的水消費量和碳排放
• 隨著重磅單株抗體專利到期，生物相似藥合約服務應運而生。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章生技藥品受託製造廠商市場（按服務類型分類）

• 製藥
• 原料藥

第9章生技藥品合約開發及受託製造廠商市場（按表現系統）

• 哺乳動物
  • CHO細胞
  • HEK細胞
  • Ns0細胞
• 微生物
  • 大腸桿菌
  • 酵母菌

第10章生技藥品受託製造廠商市場（按治療類別分類）

• 免疫學
• 感染疾病
• 神經病學
• 腫瘤學

第11章生技藥品受託製造廠商市場（依開發階段分類）

• 商業的
• 第一階段
• 第二階段
• 第三階段
• 臨床前

第12章生技藥品合約開發和受託製造廠商市場（按最終用戶分類）

• 生技中小企業
• 合約研究組織
• 大型製藥公司

第13章生技藥品合約開發與受託製造廠商市場（按地區分類）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章生技藥品合約開發與受託製造廠商市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 各國生技藥品合約開發與受託製造廠商市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Lonza Group AG
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • WuXi Biologics（Cayman）Inc.
  • Thermo Fisher Scientific Inc.
  • Fujifilm Diosynth Biotechnologies USA, Inc.
  • Patheon, Inc.
  • AGC Biologics Inc.
  • Merck KGaA

The Biologics Contract Development & Manufacturing Organization Market is projected to grow by USD 19.18 billion at a CAGR of 7.69% by 2032.

An incisive introduction highlighting how technological, regulatory, and commercial forces are reshaping biologics CDMO partnerships and operational priorities

The biologics contract development and manufacturing landscape is entering a period of strategic recalibration driven by technological advancement, heightened regulatory expectations, and intensified competitive dynamics. Organizations of all sizes are reassessing how they partner with external manufacturers to bring complex molecules from discovery through commercialization, while simultaneously navigating supply chain fragility and workforce constraints. The interplay between advanced expression systems, evolving therapeutic modalities, and the operational needs of developers has created new benchmarks for quality, speed, and flexibility that incumbent players must meet to remain relevant.

Against this backdrop, industry stakeholders increasingly prioritize end-to-end partnerships that deliver technical depth alongside commercial agility. Innovative service models, including integrated drug substance and drug product capabilities, are redefining customer expectations and enabling faster transitions across development phases. Furthermore, investments in single-use technologies, modular facilities, and digital process controls are not merely cost-management tactics but strategic enablers that support both scalability and regulatory compliance. Taken together, these forces are reshaping how sponsors select partners, structure contracts, and plan long-term supply strategies, setting the stage for a more resilient and innovation-driven market environment.

How rapid technological advances, strategic consolidation, and shifting sponsor expectations are creating new competitive dynamics and partnership models in biologics manufacturing

The biologics manufacturing ecosystem is experiencing transformative shifts as sponsors and service providers adapt to a new set of imperatives: faster time-to-clinic, higher regulatory scrutiny, and the need for flexible manufacturing capacity that supports diverse modalities. Advances in expression systems and downstream processing are enabling higher yields and greater product consistency, while parallel developments in analytics and digital process monitoring are elevating expectations for traceability and quality assurance. These technological shifts are complemented by strategic shifts: more sponsors are moving from transactional outsourcing to strategic alliances that embed co-development and risk-sharing arrangements.

Concurrently, market dynamics are driving consolidation and specialization. Large-scale strategic investments are being directed toward capacity that supports mammalian cell expression for complex monoclonal antibodies and cell therapy supply chains, while niche providers are differentiating through microbial systems optimized for rapid recombinant protein production. This divergence is prompting sponsors to adopt hybrid sourcing strategies that pair flexible, small-scale capacity for early-stage development with robust commercial-scale partners for later-stage manufacturing. As a result, long-term supplier relationships, investment in platform technologies, and the ability to pivot between expression systems and development phases are becoming core determinants of competitive advantage. Policymakers and regulators are also influencing these shifts by emphasizing supply chain transparency and quality metrics, which further shapes capital allocation and operational design across the sector.

Understanding how projected trade policy shifts and tariff adjustments could reshape sourcing, capacity allocation, and supplier strategies across biologics development and manufacturing

Anticipated tariff changes and trade policy adjustments in 2025 present a complex set of considerations for biologics supply chains, procurement strategies, and cross-border manufacturing partnerships. Tariffs can materially influence the landed cost of critical raw materials, single-use consumables, and certain components of fill-finish and packaging operations, leading organizations to reassess sourcing geographies and contractual terms. In response, sponsors and contract manufacturers may accelerate supplier diversification, establish regional sourcing hubs, or renegotiate long-term supply agreements to mitigate potential cost volatility and preserve production timelines.

Beyond direct input costs, tariff-driven shifts can have second-order effects on project planning and capacity allocation. For example, higher import duties on certain equipment or consumables could incentivize onshoring of specific manufacturing steps, particularly those with specialized regulatory oversight or cold-chain dependencies. Such moves would alter capital deployment decisions and may prioritize investments in modular, relocatable assets that reduce exposure to cross-border tariff risk. Additionally, logistics complexity may rise as firms seek to avoid tariff exposure through multi-leg routing or localized warehousing, which in turn creates operational friction and potential delays. Importantly, regulatory compliance remains non-negotiable; any adjustments to sourcing or manufacturing location must account for validation requirements and supply chain transparency obligations to avoid downstream approval setbacks. Overall, prudent scenario planning, flexible contract terms, and strengthened supplier relationships will be essential tools for mitigating the cumulative impacts of trade policy shifts on biologics development and commercialization.

Segmentation-driven insights revealing how service types, expression platforms, therapeutic focus, development phase needs, and end-user profiles dictate CDMO capabilities and strategic priorities

A nuanced segmentation lens reveals meaningful differences in demand drivers, operational requirements, and value propositions across service types, expression systems, therapeutic categories, development phases, and end users. Based on service type, the market distinguishes between drug product and drug substance services, each demanding specific technical capabilities and regulatory processes and prompting different partner selection criteria. Based on expression system, providers and sponsors evaluate trade-offs between mammalian and microbial platforms; mammalian systems require deep expertise in Cho, Hek, and Ns0 cell lines for complex glycosylated proteins, while microbial approaches such as E coli and yeast excel at rapid, cost-effective production for less complex molecules.

Based on therapeutic category, customer requirements vary significantly across immunology, infectious disease, neurology, and oncology, with oncology often necessitating highly tailored development pathways and immunology prioritizing robust scale-up capability. Based on development phase, needs evolve from preclinical and Phase I, where speed and flexibility are paramount, through Phase II and Phase III, where process robustness and scalable supply chain architectures become critical, to commercial stage where long-term capacity commitments, regulatory stability, and cost efficiency dominate decision criteria. Based on end user, expectations differ between biotech small and medium enterprises, contract research organizations, and large pharmaceutical firms; smaller biotech clients often prioritize agility and deep technical partnership, while large pharma typically seeks integrated global networks and stringent compliance systems. Together, these segmentation dimensions define the contours of demand and inform where investments in capability, quality systems, and commercial models will deliver the greatest strategic value.

Regional landscape analysis showing how the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct advantages and strategic considerations for biologics manufacturing

Regional dynamics continue to shape investment decisions, operational footprints, and partnership strategies across the global biologics manufacturing landscape. In the Americas, strengths include established regulatory frameworks, deep capital pools for facility expansion, and a concentration of sponsors requiring large-scale mammalian manufacturing capacity; this region often emphasizes integration with domestic clinical development programs and prioritizes supply chain resilience through localized capabilities. Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with regional specialization, enabling a mix of high-quality contract services for both niche and commercial-scale programs and fostering collaboration across national centers of excellence.

Asia-Pacific is distinguished by rapid capacity growth, competitive cost structures, and an expanding pool of technical talent, making it an important hub for both early-stage development work and commercial manufacturing for export-oriented clients. However, cross-border regulatory alignment and technology transfer considerations remain important when leveraging regional capacity. Across all regions, stakeholders increasingly factor in geopolitical dynamics, logistics complexity, and the availability of skilled workforce when making siting and partnership decisions. Strategic regional diversification, coupled with adherence to global quality standards and proactive regulatory planning, helps sponsors manage operational risk while accessing the advantages each region offers for different phases of product development and commercialization.

Corporate strategies and capability-building trends among major and niche service providers that are driving competitive differentiation and long-term resilience in biologics manufacturing

Leading companies and innovative entrants are pursuing differentiated strategies to secure resilient revenue streams and technological leadership in biologics contract development and manufacturing. Many incumbent providers are expanding end-to-end capabilities to capture value across drug substance and drug product workflows, investing in modular facilities and single-use platforms to increase throughput flexibility while lowering up-front capital intensity. Others are focusing on specialized niches, such as advanced analytics, high-potency manufacturing, or gene and cell therapy supply chains, to command premium positioning where deep scientific expertise is a decisive competitive moat.

Strategic partnerships and alliance models are increasingly prominent, with sponsors seeking collaborators that can co-invest in platform development or capacity expansions. Digitalization and automation investments are being leveraged not only to increase operational efficiency but also to enhance data integrity, regulatory readiness, and remote process monitoring-capabilities that are especially attractive to global pharmaceutical clients. Talent and knowledge management remain critical differentiators; firms that combine robust training programs with cross-functional scientific teams are better positioned to support complex transfer projects and accelerated timelines. Finally, environmental, social, and governance priorities are becoming integral to corporate strategies, with sustainability initiatives increasingly influencing customer selection and long-term contractual negotiations.

Practical, high-impact actions that senior executives and operational leaders can implement to improve flexibility, reduce execution risk, and strengthen competitive positioning in biologics CDMO operations

Industry leaders can take decisive steps to preserve agility, manage risk, and capture growth opportunities in a rapidly evolving biologics manufacturing ecosystem. First, prioritize flexible platform investments that support multiple expression systems and scalable downstream processing to accommodate shifting client mixes and therapeutic modalities; such flexibility reduces revalidation burdens and shortens technology transfer timelines. Second, strengthen supplier relationships through multi-year strategic agreements with clear governance and contingency clauses that address trade policy volatility and raw material availability. Third, accelerate adoption of digital process control and advanced analytics to improve yield, reduce batch failures, and demonstrate superior data integrity to regulators.

In addition, diversify regional capacity strategically rather than uniformly, aligning facility types to regional advantages-early-phase development hubs in regions offering rapid turnaround and commercial-scale production in regions with proven regulatory alignment. Invest in workforce development and cross-training programs to mitigate talent bottlenecks and ensure continuity during scale-up or transfer activities. Finally, incorporate sustainability and ESG metrics into operational planning to meet emerging customer expectations and regulatory disclosure trends; this includes evaluating circular supply chain opportunities for single-use systems and reducing energy and water footprints where feasible. By implementing these measures, leaders can reduce execution risk, improve customer retention, and position their organizations for sustained competitiveness in a dynamic market.

A transparent and rigorous research methodology combining expert interviews, documentation review, and data triangulation to produce validated actionable insights for biologics manufacturing stakeholders

The research underpinning these insights was developed through a structured methodology that combined targeted primary engagement with subject-matter experts and rigorous secondary-source validation. Primary research included in-depth interviews with technical leaders, regulatory affairs professionals, and commercial executives across a spectrum of sponsors and service providers, enabling nuanced understanding of operational constraints and customer decision criteria. Secondary research involved a systematic review of regulatory guidance, patent landscapes, technology white papers, and publicly available company disclosures to contextualize primary findings and identify persistent industry patterns.

Data triangulation was applied throughout to reconcile divergent perspectives and validate conclusions, with special attention given to cross-referencing interview findings against facility filings, regulatory approvals, and equipment vendor capabilities. Segmentation mapping was employed to align capability indicators with service types, expression systems, therapeutic categories, development phases, and end-user profiles, ensuring that recommendations were grounded in empirically observed behaviors. Finally, limitations and potential biases were explicitly considered, including geographic sampling constraints and respondent confidentiality concerns, and were mitigated through methodological transparency and iterative validation with independent experts.

A concise conclusion emphasizing the strategic shifts, imperative investments, and collaborative approaches needed to thrive in the evolving biologics CDMO ecosystem

In conclusion, the biologics contract development and manufacturing sector is being reshaped by technological innovation, evolving sponsor preferences, and an increasingly complex geopolitical and regulatory environment. These forces are driving a shift toward more strategic, integrated partnerships and compelling service providers to invest in flexible platforms, enhanced analytics, and robust quality systems. Sponsors, in turn, are seeking partners that can balance speed with regulatory rigor and provide secure, diversified supply chains capable of supporting both rapid development and long-term commercialization.

Looking forward, organizations that proactively address tariff-driven supply risks, align regional investments with strategic therapeutic priorities, and adopt digital and sustainability-focused practices will be better positioned to meet the demands of next-generation biologics programs. Collaboration across the ecosystem-between technology vendors, contract providers, and sponsors-will be critical to accelerate capability development and to ensure that operational changes translate into reliable patient access. The collective ability to manage complexity while maintaining regulatory compliance and scientific excellence will determine which organizations emerge as preferred long-term partners in the biologics era.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of cell and gene therapy manufacturing capabilities to meet growing personalized medicine demand
• 5.2. Rise of single-use bioreactor adoption to drive operational flexibility and contamination risk reduction
• 5.3. Implementation of continuous upstream and downstream bioprocessing to accelerate time to market
• 5.4. Integration of digital twin technologies for real-time monitoring and process optimization in biologics
• 5.5. Strategic partnerships between CDMOs and pharmaceutical innovators for antibody-drug conjugate scale-up
• 5.6. Adoption of advanced process analytical technology platforms for inline quality control in biomanufacturing
• 5.7. Development of modular facility designs enabling rapid capacity expansion for multi-product biologic pipelines
• 5.8. Utilization of AI-driven predictive maintenance to minimize unplanned downtime in biologics production facilities
• 5.9. Investment in sustainable manufacturing practices to reduce water consumption and carbon emissions in biologics
• 5.10. Emergence of biosimilar contract services to capitalize on patent expirations of blockbuster monoclonal antibodies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development & Manufacturing Organization Market, by Service Type

• 8.1. Drug Product
• 8.2. Drug Substance

9. Biologics Contract Development & Manufacturing Organization Market, by Expression System

• 9.1. Mammalian
  • 9.1.1. Cho
  • 9.1.2. Hek
  • 9.1.3. Ns0
• 9.2. Microbial
  • 9.2.1. E Coli
  • 9.2.2. Yeast

10. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category

• 10.1. Immunology
• 10.2. Infectious Disease
• 10.3. Neurology
• 10.4. Oncology

11. Biologics Contract Development & Manufacturing Organization Market, by Development Phase

• 11.1. Commercial
• 11.2. Phase I
• 11.3. Phase Ii
• 11.4. Phase Iii
• 11.5. Preclinical

12. Biologics Contract Development & Manufacturing Organization Market, by End User

• 12.1. Biotech Small Med
• 12.2. Contract Research Org
• 12.3. Large Pharma

13. Biologics Contract Development & Manufacturing Organization Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Biologics Contract Development & Manufacturing Organization Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Biologics Contract Development & Manufacturing Organization Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Lonza Group AG
  • 16.3.2. Catalent, Inc.
  • 16.3.3. Samsung Biologics Co., Ltd.
  • 16.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
  • 16.3.5. WuXi Biologics (Cayman) Inc.
  • 16.3.6. Thermo Fisher Scientific Inc.
  • 16.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • 16.3.8. Patheon, Inc.
  • 16.3.9. AGC Biologics Inc.
  • 16.3.10. Merck KGaA

LIST OF FIGURES

• FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGA